Postmenopausal hormone replacement therapy and major clinical outcomes: A focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia

American Journal of Managed Care

Volumn 8, Issue 1, 2002, Pages 95-104

  Dick, Sarah E ^a   DeWitt, Dawn E ^a   Anawalt, Bradley D ^a  

^a Puget Sound VA Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTILIPEMIC AGENT; ANTITHROMBIN III; APOLIPOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SIMVASTATIN; TACRINE; UNINDEXED DRUG; VITAMIN D;

BREAST CANCER; BREAST TUMOR; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG USE; ENDOMETRIUM TUMOR; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; POPULATION RISK; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; THROMBOEMBOLISM; TREATMENT PLANNING;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DEMENTIA; EDUCATION, MEDICAL, CONTINUING; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0036162556     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women
2. Menopause and heart disease: A review
3. A prospective observational study of post-menopausal hormone therapy and primary prevention of cardiovascular disease
4. Hormone therapy to prevent disease and prolong life in postmenopausal women
5. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement study (HERS) Research Group
6. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
7. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population
8. Hormone replacement therapy, heart disease, and other considerations
9. Postmenopausal hormone therapy and mortality
10. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
11. Cardiovascular effects of estrogen and lipid lowering therapies in postmenopausal women
12. The protective effects of estrogen on the cardiovascular system
13. The HERS trial results: Paradigms lost?
14. Overview of results of randomized clinical trials in heart disease: 1. Treatments following myocardial infarction
15. Effect of beta-blockade among high risk and low risk patients after myocardial infarction
16. National use and effectiveness of beta blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
18. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
20. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
21. Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene
22. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
24. A prospective study of aspirin use and primary prevention of cardiovascular disease in women
25. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic postmenopausal women
26. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
27. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group
28. Hormone replacement therapy
29. Effects of hormone therapy on bone mineral density: Results from the PEPI trial
30. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study)
31. Estrogen replacement therapy and fractures in older women
32. Patient-specific decisions about hormone replacement therapy in postmenopausal women
33. Hormone replacement therapy and risk of hip fracture: A case control study
34. Hormone replacement therapy and prevention of nonvertebral fractures
35. Prevention of bone loss with alendronate in postmenopausal women under sixty years of age
36. Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporotic women
37. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
38. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
39. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis. A randomized controlled trial
40. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
41. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
42. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
43. Effect of risedronate on the risk of hip fracture in elderly women
44. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
45. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
46. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
47. Selective estrogen receptor modulators: Clinical spectrum
48. Effect of calcitonin on vertebral and other fractures
49. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study (PROOF)
50. 3 and calcium to prevent hip fracture in elderly women
51. Drugs for prevention and treatment of postmenopausal osteoporosis
52. Estrogen replacement therapy and cognitive function in older women
53. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women
54. Estrogen improves psychological function in asymptomatic postmenopausal women
55. Effects of estrogen on memory function in surgically menopausal women
56. Hormone replacement therapy and cognition: Systematic review and analysis
57. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project
58. Cognitive function in postmenopausal women treated with raloxifene
59. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
60. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
61. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled double blind study
62. Estrogen for Alzheimer's disease in women: Randomized double-blind, placebo-controlled trial
63. Estrogen replacement therapy for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
64. Treatment of Alzheimer's disease
65. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
66. Breast cancer and hormonal contraceptives: Further results
67. Hormone replacement therapy and breast cancer risk in a nationally representative cohort
68. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone
69. Risks of breast and endometrial cancer after estrogen and progestin replacement
70. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
71. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
72. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
73. Hormone replacement and the risk of breast cancer with favorable histology: Results of the Iowa Women's Health Study
74. Estrogen replacement therapy and the risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
75. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
76. Cyclic hormone replacement therapy using quarterly progestin
77. Progestogen supplementation of exogenous estrogens and the risk of endometrial cancer
78. Risk of endometrial cancer following estrogen replacement with and without progestins